Keratoconus Market

At present, most of the pharma giants consider Keratoconus as a rare disease; there is often a debate on the understanding of the actual prevalence of the disease.
Since the 90s, the advancement in diagnostic tools such as corneal topography has soared the diagnosis rate at a commendable rate. The improvement, recognition, and research progress has made the disease well-known.
Keratoconus awareness has prompted significant development of new and improved interventions that augment the established legacy treatments.

Sooft Italia, Peschke Meditrade GmbH, and Lightmed-OptiMed and Avedro, Inc. are some of the key players involved in developing therapies for Keratoconus.

For more details, visit: https://www.delveinsight.com/blog/keratoconus-market/